title: The effect of niacinamide on osteoarthritis: a pilot study.
abstract: OBJECTIVE
  To evaluate the effect of niacinamide, on selected parameters of osteoarthritis using a double-blind, placebo controlled study design.
  
  
  METHODS
  Seventy two patients with osteoarthritis were randomized for treatment with niacinamide or an identical placebo for 12 weeks. Outcome measures included global arthritis impact and pain, joint range of motion and flexibility, erythrocyte sedimentation rate, complete blood count, liver function tests, cholesterol, uric acid, and fasting blood sugar. Compliance was monitored with a pill record sheet and interview.
  
  
  RESULTS
  Global arthritis impact improved by 29% (95% confidence interval [CI] 6, 46) in subjects on niacinamide and worsened by 10% in placebo subjects (p = 0.04). Pain levels did not change but those on niacinamide reduced their anti-inflammatory medications by 13% (95% CI 9, 94; p = 0.01). Niacinamide reduced erythrocyte sedimentation rate by 22% (95% CI 6, 51; p < 0.005) and increased joint mobility by 4.5 degrees over controls (8 degrees vs 3.5 degrees; p = 0.04). Side effects were mild but higher in the niacinamide group (40% vs 27%, p = 0.003).
  
  
  CONCLUSIONS
  This study indicates that niacinamide may have a role in the treatment of osteoarthritis. Niacinamide improved the global impact of osteoarthritis, improved joint flexibility, reduced inflammation, and allowed for reduction in standard anti-inflammatory medications when compared to placebo. More extensive evaluation of niacinamide in arthritis is warranted.
authors.affiliation: Office of Alternative Medicine, National Institute of Health, Bethesda, MD 20892, USA.
authors.forename: W B
authors.initials: WB
authors.lastname: Jonas
authors.forename: C P
authors.initials: CP
authors.lastname: Rapoza
authors.forename: W F
authors.initials: WF
authors.lastname: Blair
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D010349:Patient Compliance; D010865:Pilot Projects
chemical_list: D009536:Niacinamide